1 Department of Pharmacognosy, Medical University of Bialystok, Bialystok, Poland.
Am J Chin Med. 2018;46(2):319-337. doi: 10.1142/S0192415X18500167. Epub 2018 Feb 12.
Flavonoid compound scutellarin (Scu) is quite frequently met in the plant kingdom, particularly in the genus Scutellaria (Lamiaceae) and Erigeron (Asteraceae). The extract of the herb of Erigeron breviscapus, containing this component in high amount, has been used for many years in traditional Chinese medicine. In recent years, studies have made great progress on the usefulness of Scu for treating various diseases by testing its mechanism of action. They support the traditional use of Scu rich plant in heart and cerebral ischemia. Scu can potentially be applied in Alzheimer's disease, Helicobacter pylori infection, vascular complications of diabetes and as an inhibitor of certain carcinomas. Various methods were designed to improve its isolation from plant material, solubility, absorption and bioavailability. On the basis of recent studies, it is suggested that Scu could be a promising candidate for new natural drug and deserves particular attention in further research and development.
黄酮类化合物野黄芩苷（Scu）在植物界中相当常见，特别是在黄芩属（唇形科）和菊科飞蓬属中。含有大量这种成分的短葶飞蓬草的提取物多年来一直被用于中药。近年来，通过研究其作用机制，野黄芩苷在治疗各种疾病方面的用途取得了很大进展。它们支持了富含野黄芩苷的植物在心脏和大脑缺血方面的传统用途。野黄芩苷有可能应用于阿尔茨海默病、幽门螺杆菌感染、糖尿病血管并发症和某些癌的抑制剂。已经设计了各种方法来提高其从植物材料中的分离度、溶解度、吸收率和生物利用度。基于最近的研究，建议野黄芩苷可能是一种有前途的新型天然药物候选物，值得在进一步的研究和开发中给予特别关注。
